Expression of GAS5 has been shown to be downregulated in a variety of cancers, such as lung, breast, bladder, gastric, prostate, and pancreatic cancer [75], suggesting that GAS5 may play a tumor suppressor role during cancer progression. Here, GAS5 is linked to familial pancreatic carcinoma.